Insights from a phase II clinical trial with CL2020 Muse cell-based therapeutic for Amyotrophic lateral sclerosis
Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease characterized by progressive loss of motor functions, which eventually leads to death within 5 years of its...